{"id":"standard-maintenance-immunosuppression","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Bone loss/osteoporosis"},{"rate":null,"effect":"Malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not a single drug but rather a clinical protocol combining multiple immunosuppressive agents (typically calcineurin inhibitors, corticosteroids, and antimetabolites) to maintain long-term graft tolerance. The combination approach targets different points in the immune cascade to provide synergistic suppression while minimizing individual drug toxicity through dose optimization.","oneSentence":"Standard maintenance immunosuppression refers to a combination regimen of immunosuppressive agents used to prevent organ rejection in transplant recipients by suppressing T-cell and B-cell mediated immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:19.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in solid organ transplant recipients (kidney, heart, liver, lung)"},{"name":"Maintenance of graft function in transplant patients"}]},"trialDetails":[{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06568549","phase":"PHASE4","title":"Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-06-13","conditions":"Kidney Transplantation, Mycophenolate Mofetil","enrollment":350},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT02113891","phase":"PHASE1, PHASE2","title":"Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation","enrollment":""},{"nctId":"NCT04678401","phase":"PHASE1","title":"IS-free Treg HaploHCT","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-12","conditions":"Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute","enrollment":30},{"nctId":"NCT07045467","phase":"PHASE1","title":"Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-07-01","conditions":"Chronic Kidney Diseases, Renal Transplantation","enrollment":30},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT05220397","phase":"PHASE3","title":"Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Mark Stegall","startDate":"2022-04-11","conditions":"Kidney Transplant Recipient","enrollment":468},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT06055556","phase":"NA","title":"Partial Heart Transplantation","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2023-08-04","conditions":"Congenital Heart Disease","enrollment":""},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT04720326","phase":"PHASE4","title":"Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Geissler","startDate":"2020-12-23","conditions":"Prophylaxis Against Liver Transplant Rejection","enrollment":268},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT04225988","phase":"PHASE4","title":"Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-01-09","conditions":"Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":"Uterus Transplant","enrollment":""},{"nctId":"NCT03995901","phase":"PHASE3","title":"A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation","status":"TERMINATED","sponsor":"Talaris Therapeutics Inc.","startDate":"2019-10-25","conditions":"Transplanted Organ Rejection","enrollment":15},{"nctId":"NCT03591380","phase":"PHASE2","title":"CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-14","conditions":"Kidney Transplantation","enrollment":3},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT00807144","phase":"PHASE4","title":"Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation","status":"COMPLETED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2008-12","conditions":"End-stage Renal Failure, Graft Rejection","enrollment":102},{"nctId":"NCT02544113","phase":"PHASE2","title":"A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2015-12","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT03386305","phase":"PHASE2, PHASE3","title":"Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albert Einstein Healthcare Network","startDate":"2017-12-13","conditions":"Post Liver Transplant","enrollment":35},{"nctId":"NCT01655563","phase":"PHASE2","title":"Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2011-09","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":75},{"nctId":"NCT01327573","phase":"PHASE1","title":"Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation","status":"COMPLETED","sponsor":"Sanjay Kulkarni","startDate":"2011-03","conditions":"Kidney; Complications, Allograft","enrollment":16},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT00407160","phase":"","title":"A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2004-08","conditions":"Kidney Diseases","enrollment":21},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT02581436","phase":"NA","title":"Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2014-09","conditions":"Disorder Related to Renal Transplantation, Renal Transplant Rejection, Acute Graft Rejection","enrollment":70},{"nctId":"NCT01998789","phase":"PHASE2","title":"Everolimus Post Orthotopic Liver Transplant","status":"UNKNOWN","sponsor":"Tomoaki Kato","startDate":"2013-10","conditions":"Orthotopic Liver Transplant","enrollment":50},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT01005316","phase":"","title":"Alloantibodies in Pediatric Heart Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients","enrollment":290},{"nctId":"NCT03005236","phase":"PHASE4","title":"AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2017-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT01025817","phase":"PHASE3","title":"Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Kidney Transplant","enrollment":613},{"nctId":"NCT00765661","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Failure, Renal Failure","enrollment":63},{"nctId":"NCT00133172","phase":"PHASE4","title":"Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2005-07","conditions":"Kidney Transplantation","enrollment":85},{"nctId":"NCT00472082","phase":"PHASE1, PHASE2","title":"Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Emory University","startDate":"2007-05","conditions":"Kidney Transplantation, Chronic Kidney Failure","enrollment":5},{"nctId":"NCT00311311","phase":"PHASE3","title":"Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Atherosclerosis, Kidney Failure","enrollment":72},{"nctId":"NCT01877746","phase":"PHASE3","title":"CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)","status":"UNKNOWN","sponsor":"St. Anne's University Hospital Brno, Czech Republic","startDate":"2013-01","conditions":"Inflammatory Cardiomyopathy","enrollment":234},{"nctId":"NCT00587158","phase":"NA","title":"Oral Paricalcitol in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary","enrollment":100},{"nctId":"NCT00214279","phase":"NA","title":"MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2002-05","conditions":"Renal Transplantation","enrollment":32},{"nctId":"NCT01276457","phase":"PHASE3","title":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Transplantation Infection","enrollment":223},{"nctId":"NCT00434590","phase":"PHASE4","title":"Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-03","conditions":"Kidney Transplantation","enrollment":10},{"nctId":"NCT00966836","phase":"PHASE3","title":"Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2009-04","conditions":"Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"standard maintenance immunosuppression","genericName":"standard maintenance immunosuppression","companyName":"University of Sao Paulo General Hospital","companyId":"university-of-sao-paulo-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard maintenance immunosuppression refers to a combination regimen of immunosuppressive agents used to prevent organ rejection in transplant recipients by suppressing T-cell and B-cell mediated immune responses. Used for Prevention of organ rejection in solid organ transplant recipients (kidney, heart, liver, lung), Maintenance of graft function in transplant patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}